🟢 Summit Therapeutics is trading 4.3% up today in a rebound from prior declines

Summit Therapeutics is trading at $14.08 (up 4.3%) as the stock rebounds from prior declines linked to ivonescimab trial and regulatory overhangs.

• The move comes as the stock outperforms a weak biotech sector and firmer broader indices, despite a lack of fresh company-specific news or earnings.
• Investors remain focused on the upcoming FDA BLA action date in November 2026 and multiple ongoing Phase III clinical studies.